专利摘要:
METHODS AND COMPOSITIONS INCLUDING SPORE-FORMING BACTERIA TO INCREASE ANIMALS HEALTH. Methods, compositions and bacterial isolates for improving the gastrointestinal health of animals and in particular poultry are provided herein. The methods include administering a spore-forming bacterium to an animal. Bacteria are selected for their ability to reduce growth and the presence of bacterial pathogens, such as Salmonella, Clostridium, and Campylobacter, in the animal's gastrointestinal tract. Bacteria are also selected for their ability to improve at least one production parameter in the animal.
公开号:BR112013001107B1
申请号:R112013001107-6
申请日:2011-07-18
公开日:2022-01-25
发明作者:Ross Wolfenden;Neil R. Pumford;Marion Morgan;Anita Menconi;Guillermo Tellez;Amanda Wolfenden;Srichaitanya Shivaramaiah;Billy Hargis
申请人:The Board Of Trustees Of The University Of Arkansas;
IPC主号:
专利说明:

REFERENCES TO RELATED APPLICATIONS
[001] This patent application claims the priority benefit of United States Provisional Patent Application No. 61/365,188, filed July 16, 2010, which is incorporated herein by reference in its entirety. DECLARATION REGARDING FEDERALLY SPONSORED RESEARCH
[002] This invention was made with support from the United States government under grant number 2010-34211-20961 from the United States Department of Agricultural Food Safety Consortium. The United States has certain rights in this invention. FIELD OF THE INVENTION
[003] The present invention relates to methods in general for improving the health of agricultural animals. In particular, the present invention relates to bacterial isolates, probiotic formulations which encompass bacterial isolates, probiotic formulations which encompass the isolates, and methods of selecting and using probiotic formulations to improve the health of poultry. HISTORY OF THE INVENTION
[004] The use of antibiotics in agricultural animals, in particular in poultry production, is coming under increasing pressure from both consumers and government regulatory agencies. This has created a need for effective antibiotic alternatives. The use of effective probiotics or microbials for direct inclusion (DFM) in agricultural animals could be a potential alternative. Currently, there are two general subsets of bacteria used in DMF or probiotic applications: Lactic acid bacteria and Bacillus spp.
[005] While some isolates are proven to be effective, lactic acid bacteria have the disadvantage that they must be applied via drinking water. This is because these two types of organisms are generally not tolerant of the heat needed to crowd many animal feed diets. Furthermore, since these products must be applied via water, the individual farmer is responsible for applying the product. This often leads to issues of compliance with proper management recommendations leading to improper application and reduced effectiveness of these products. SUMMARY OF THE INVENTION
[006] Methods for improving the health of the gastrointestinal tract in animals, bacterial isolates and probiotic formulations which encompass these isolates are set forth herein. Bacterial isolates are Bacillus spp. Selected from environmental sources that are able to improve poultry health. These isolates were selected for the ability to 1) reduce Salmonella or other foodborne bacteria pathogenic to humans, 2) improve production parameters in commercial poultry operations, or 3) reduce poultry enteric bacterial pathogens. No known DFM Bacillus product, Bacillus isolate, or combination of Bacillus isolates is capable of performing all three tasks.
[007] On the one hand, methods for improving the health of the gastrointestinal tract in animals are provided. The methods include administering a spore-forming bacterium to an animal. Spore-forming bacteria are able to reduce the number or growth of bacterial pathogens in the animal's gastrointestinal tract. Furthermore, the administration of the spore-formed bacteria to the animal improves at least one animal production parameter.
[008] On the other hand, bacterial isolates selected using methods disclosed herein are provided and include Bacillus subtilis AM0904 (NRR1 Deposit Number B-50914), Bacillus subtilis AM0911 (NRRL Deposit Number B-50915), Bacillus subtilis NP122 (NRRL Deposit Number B-50910), Bacillus subtilis NP119B (NRRL Deposit Number B-50909), B. licheniformis B1 (NRRL Deposit Number B-50907), B. subtilis B2 (NRRL Deposit Number B-50908), B licheniformis RW25 (NRRL Deposit Number B-50911), B. licheniformis RW32 (NRRL Deposit Number B-50912), and B. licheniformis RW41 (NRRL Deposit Number B-50913).
[009] On the other hand, the multi-isolate combinations and probiotic compositions of the disclosed bacterial isolates are provided herein. In one embodiment, a combination of B. subtilis (one or more distinct isolates or strains) and/or B. licheniformis (at least one isolate) is provided. The bacterial isolates and probiotic formulations provided by the present advance on current technology as they increase the performance of commercial poultry, decrease common bacterial pathogens within the gut of commercial poultry, and reduce bacteria associated with broiler disease. food source, such as Salmonella, from within the intestine of commercial poultry.
[010] In another aspect, animal feed comprising the disclosed probiotic compositions or bacterial isolates is provided herein. Feed may include 104 and 10' cfu/gm ready feed.
[011] In yet another aspect, methods for improving the health of poultry are provided. The methods include administering the probiotics or animal feed formulation described herein to an animal. The animal's gastrointestinal health can be improved through the method.
[012] In yet another aspect, methods of selecting bacterial strains for use in probiotic formulations are provided. Methods include selecting facultative bacterial strains capable of forming spores, selecting bacterial strains capable of reducing the growth of pathogenic bacteria such as Salmonella enteritidis, Salmonella typhimurium, Campylobacter jejuni or Clostridium perfringens in mixed cultures in vitro or in the gastrointestinal tract of animals, selecting strains bacteria capable of improving the growth rate of commercial poultry, reducing the severity of necrotic and/or persistent enteritis in the gastrointestinal tract and removing any selected bacterial strains not considered GRAS (Generally Recognized as Safe) by the Food and Drug Administration (FDA), ineligible for inclusion in animal feed through the American Association of Food Control Official (AAFCO) or capable of hemolysis of sheep red blood cells. BRIEF DESCRIPTION OF THE FIGURES
[013] A more complete understanding of the present invention may be derived by referring to the detailed description and claims when considered in connection with the Figures.
[014] Figure 1 is a diagram of the in vitro portion of the isolate selection procedures used to isolate and select DFM/probiotic candidate isolates.
[015] Figure 2 is a diagram of the in vivo portion of the isolate selection procedures used to isolate and select DFM isolates/probiotic candidates. DETAILED DESCRIPTION
[016] Methods, compositions and bacterial isolates for improving the gastrointestinal health of poultry are disclosed. The compositions include probiotic or Direct Inclusion Microbial (DFM) formulations and animal feed products. Delivery methods for improving animal health and reducing contamination of the human food chain for isolated specific bacterial strains useful in the methods are also disclosed. The methods and compositions provided herein also produce great consistency of production within the group of animals.
[017] Methods for improving the health of the gastrointestinal tract in animals include administering a spore-forming bacterium to an animal. Bacteria can be administered as spores, but may not be. Spore-forming bacteria are able to reduce the number or growth of bacterial pathogens in the animal's gastrointestinal tract. The number of bacterial pathogens within the gastrointestinal tract is reduced in animals administering the spore-forming bacteria when compared to control animals not administering the bacteria. Bacterial pathogens refer to bacteria capable of causing disease, such as morbidity or mortality, both in animals being administered the bacteria and in humans. Pathogenic bacteria also include those bacteria capable of causing foodborne illness in humans.
[018] Spore-forming bacteria can be any bacteria capable of sporulation such as those of the genus Bacillus, in particular Bacillus subtilis or Bacillus licheniformis. Spore-forming bacteria are properly non-pathogenic, that is, they are not capable of causing morbidity or mortality in the animals being treated. Suitably the bacteria are facultative anaerobes and capable of reproducing and/or persisting within the intestinal tract of the animal. Properly, the bacteria are Generally Recognized as Safe (GRAS) by the United States Food and Drug Administration (FDA) and acceptable for inclusion in an animal diet or water by the American Association of Food Control Officials (AAFCO). Properly spore-forming bacteria are not capable of causing hemolysis when incubated with or cultured on media containing red blood cells. Properly spore-forming bacteria are able to reduce the growth of at least one pathogenic bacterium.
[019] Administration of the bacteria improves the gastrointestinal health of the animal. Gastrointestinal health includes prevention of disease of the gastrointestinal tract itself, such as necrotic enteritis of the intestines, or pathogenic bacterial load from the intestines, cecum, or small intestine, and increases in production parameters for treated animals when compared to controls. Production parameters include, but are not limited to, average daily weight gain, feed conversion rate, consistency of growth among a group of animals, ability to breed and care for healthy offspring, ability to produce eggs and milk, and the quantity and quality of such production.
[020] In one aspect, an exemplary composition or formulation may include one or more spore-forming bacteria. Bacteria capable of forming spores include bacteria of the genus Bacillus. Specific B. subtilis and B. lincheniformis bacterial isolates are disclosed herein, however other spore-forming bacteria suitable for use in the methods and composition disclosed herein may be isolated and selected by those skilled in the art using selection methods described below and in the Examples. . For example, a composition may include a formulation containing one or two B. subtilis isolates and/or one or two B. licheniformis isolates, where each isolate is independently selected to play a specific role and/or function. The combination of these isolates can be combined with an agricultural feed (poultry feed specifically) and used ultimately to improve the health and productivity of agricultural animals (eg livestock and/or poultry). For example, isolates and/or combined isolate formulations can reduce pathogenic bacteria in particular, bacteria associated with foodborne illness, which cause contamination of eggs or meat, can reduce intestinal pathogens in poultry, and increase the weight gain or egg production of poultry.
[021] Specifically, the isolates can decrease the occurrence or burden of Salmonella, Campylobacter and Clostridium. Through the reduction of C. perfringens in the gastrointestinal tract of farm animals and through other beneficial reactions of the isolates with farm animals, the occurrence of necrotic enteritis is reduced. In addition, these bacteria decrease the mortality rate of agricultural animals, and the average daily weight gain of agricultural animals is increased. In the case of poultry, a reduced level of Salmonella within the gastrointestinal tract can lead to less carcass contamination as well as reduce the likelihood of eggs contaminated with Salmonella.
[022] As described in the examples below, bacterial isolates were selected for their ability to form spores and as they are resistant to temperature extremes. The selected bacteria are facultative anaerobes and are not hemolytic. The bacteria are able to inhibit or reduce the growth of both gram-negative and gram-positive bacteria such as Salmonella, Clostridium and Campylobacte. The ability to reduce pathogenic bacterial growth allows selected bacteria to reduce necrotic enteritis in poultry. Selected bacteria are also able to increase the growth rate and gastrointestinal health of commercial poultry and are able to persist and colonize in the gastrointestinal tract of poultry. The isolates are all considered GRAS (Generally Recognized as Safe) by the FDA and are eligible for inclusion in animal feed through the AAFCO. Furthermore, these particular isolates are able to spend their entire lives within the gastrointestinal tract of agricultural animals, specifically in poultry.
[023] The bacterial isolates identified in the Examples and capable of being used in probiotic formulations or in animal feed for use in methods described herein are the following Bacillus subtilis AM0904 (NRRL Deposit Number B-50914), Bacillus subtilis AM0911 (NRRL Number B-50915), Bacillus subtilis NP122 (NRRL Deposit Number B-50910), Bacillus subtilis NP119B (NRRL Deposit Number B-50909), B. Licheniformis B1 (NRRL Deposit Number B-509907), B. subtilis B2 (NRRL Deposit Number B-50908), B. licheniformis RW25 (NRRL Deposit Number B-50911), B.licheniformis RW32 (NRRL Deposit Number B-50912), and B. licheniformis RW41 (NRRL Deposit Number B -50913). Bacterial isolates were deposited at the Agricultural Research Service Culture Collection (NRRL), 1815 North University Street, Peoria, IL 61604, United States, under the accession numbers identified above. The bacterial isolates designated as “Bacillus subtilis AM0904”, “Bacillus subtilis AM0911”, “Bacillus subtilis NP122”, “Bacillus subtilis NP119B”, “B.lincheniformis B1”, “B. lincheniformis B2”, “B. lincheniformis RW25”, “B. licheniformis RW32” and “B. licheniformis RW41” were submitted by Federal Express to the NRRL by Ross Wolfenden of the University of Arkansas on March 6, 2014.
[024] The spore, or inert, surviving form of Bacillus spp does not produce any known effects which could reduce bacterial pathogens in the gastrointestinal tract or have other beneficial effects on the animal. In contrast, the vegetative form of bacteria can produce effects. Therefore, spore reactivation and germination after administration is likely to be important for improving the gastrointestinal health of poultry. The ability of Bacillus probiotic products to germinate within the gut of commercial poultry has not been adequately investigated. The bacterial isolates described herein were also selected for their ability to reactivate, germinate and colonize or persist within animals after administration of spores of the bacteria to animals.
[025] Probiotic formulations which include at least one of the bacterial isolates provided by the present are also arranged. The probiotic formulation may include a combination of the bacterial isolates set forth herein or may include bacterial isolates other than those set forth herein. Accordingly, the bacteria used are capable of forming spores, are capable of reducing pathogenic bacterial loads in the gastrointestinal tract, and are capable of increasing at least one production parameter. For example, the probiotic formulation may include at least one Bacillus subtleis strain and/or at least one Bacillus licheniformis strain. In other examples, the probiotic formulation may include two or more Bacillus subtilis strains or two or more Bacillus licheniformis strains. Bacterial isolates can be used in any combination in probiotic formulations. For example, a combination of NP122 and B2 can be used. Alternatively, NP122 and B2 can be used in combination with AM0904 or AM0911. Any other possible combination of the bacterial isolates provided herein can also be made. The ratio of one isolate to another in a combination of a probiotic formulation can vary over a wide range. Suitably the ratio of bacterial isolates is between 0.1:1 and 10:1, suitably between 0.5:1 and 5:1, more suitably 1:1 to 3:1, more suitably between 1:1 and 2:1. In one embodiment the ratio of NP122 to B2 for AM0904 was 5.5:1. The ratios are based on the colony forming units (cfu) of bacterial spores after reactivation.
[026] The formulation of probiotics is able to improve the health of animals after administration to animals. In particular, the formulation of probiotics or animal feed comprising the formulation of probiotics is capable of improving the gastrointestinal health of poultry. This can include reducing the incidence or severity of necrotic enteritis (by at least 10%, 15% or up to 20% when compared to control, and mortality can be prevented), reducing the bacterial load in the animal's intestines, specifically with respect to levels of at least Salmonella, Campylobacter or Clostridium perfringens in the gastrointestinal tract of poultry (at least 50% decrease in recovery, suitably at least 60%, 70%, 80%, 90% or even more than a decrease in recovery when compared to control), and increase in an animal's average daily weight gain (suitably at least a 3% increase at least a 5% increase, 7%, 10%, 20%, 30%, 40% , 50%, 55%, 60% or even greater in weight gain when compared to control (mean as average daily weight gain)). The feed conversion rate can also be increased compared to the control. For example, the feed conversion rate can be increased to 2%, 3%, 5%, 7%, 10% or more.
[027] Administration of the probiotic formulation may also reduce the level or number of potential human food-borne bacterial pathogens in the gastrointestinal tract of commercial poultry. In particular, the level of Salmonella and Campylobacter spp in the gastrointestinal tract of animals administered the probiotic formulation may be reduced when compared to control animals not administered spore-forming bacteria or probiotics. Such a reduction in potential human pathogenic load in the gastrointestinal tract of poultry will limit the opportunity to contaminate the human food chain either during the preparation of meat for human consumption or through contamination of eggs or milk.
[028] These isolates, formulations of probiotics which include the isolates or animal feed which include the isolates or combinations thereof can be administered to animals orally. Oral administration includes, but is not limited to, delivery in food, water, oral gavage or aerosol spray. Suitably the animal is a farmed bird, suitably a chicken or turkey. If provided in an animal feed, the feed may include between 104 and 10' cfu of bacteria/gm of ready-to-eat feed. Suitably the feed includes between 10' and 5 x 107 cfu bacteria/gm feed. The probiotic formulation can be added to the feed during production, after production through the supplier or by the person feeding the animals, just before feeding the animals. The spore-forming bacteria used in the methods and compositions described herein are particularly suitable as they are able to survive (as spores) under the pressure and heat conditions of the dry pellet feed product production process.
[029] These isolates or combinations of isolates for inclusion in the methods and including those isolates selected and described in the Examples are selected for inclusion in agricultural animal diets for increasing total gastrointestinal health, improving production performance, and reducing bacterial pathogens enteric compounds of importance to both animal health and human food safety. These isolates alone or in combination can be added to poultry diets at a rate of approximately 104 to 10' (1.1x107 in Examples) spores per gram of finished feed for optimal inclusion rate if bacteria or probiotic compositions are administered on an ongoing basis. A higher inclusion rate may be required if bacterial spores or compositions are provided intermittently. During administration, although food is the primary route of administration, spores from these isolates may also be administered via drinking water, via course spray, aerosol spray, or via other means by which agricultural animals may ingest these isolates. or combination of isolates.
[030] Methods of isolating bacterial strains for inclusion in probiotic formulations are also provided herein and are depicted in Figures 1 and 2. Methods include both in vitro and in vivo testing to select bacteria from a source and may be complete in any order. Potential sources of bacterial isolates include animal feces, soil or environment samples, laboratory stocks or tissue bacteria, and cell supply depots such as the American Type Culture Collection (ATCC). The bacteria can then be isolated and selected by selecting facultative anaerobic bacterial strains capable of forming spores; capable of reducing the growth of or eliminating Salmonella enteritidis, Salmonella typhimurium, Campylobacter jejuni and/or Clostridium perfringens, capable of improving the growth rate of commercial poultry; capable of reducing the severity of necrotic enteritis; capable of persisting in the gastrointestinal tract of poultry. Methods also include removing bacterial strains not considered GRAS by the FDA, ineligible for inclusion in animal feed by the AAFCO, or those capable of hemolysis. Bacterial strains that meet these criteria can then be included in probiotic formulations.
[031] The present invention features exemplary isolates, compositions, and methods for improving the health of the gastrointestinal tract in animals. It will be understood that the description is of exemplary embodiments of this invention, and that the invention is not limited to the specific forms shown. Various modifications can be made in the construction and arrangement of the elements presented herein without departing from the scope of the invention. For example, the various components may be used in various combinations other than those illustrated in the exemplary embodiments, and the various steps may be carried out in different orders. These and other changes or modifications are intended to be included within the scope of the present invention. Example
[032] Environmental samples or faecal samples from poultry were collected using sterile cotton swab and placed in a sterile borosilicate tube for transport. A summary of the in vitro tests used to select bacterial isolates is presented in Figure 1. The swabs were either immersed in 50% ethanol or heated at 10°C for 15 minutes before being used to inoculate Tryptic Soy Agar (TSA) and Spizizen potato agar (SPA) to select Bacillus spp. After incubation for 24h and 72h respectively at 37°C, the resulting cultures were coated with a TSA agar containing novobiocin (NO) at 25 pg/ml and 10 6 cfu/ml Salmonella enterica serovar Enteritidis phage type 13A (SE) originally obtained from U.S. Department of Agricultural National Veterinary Services Laboratory. After incubation, those colonies which produced zones of inhibition on the SE coatings were selected for isolation. The selected colonies were pasteurized in 50% ethanol for 30 minutes then isolated on the same medium from which they were selected and incubated for either 24h (TSA) or 72h (SPA) at 37°C. The ability of the isolates to inhibit SE growth was confirmed using a second SE coating. Those isolates with confirmed in vitro ability to inhibit SE growth were expanded and selected for further analyses.
[033] The TSA plates containing sheep blood were inoculated with the isolates and incubated for 24h at 37°C. The plates were then evaluated and marked for level of hemolysis. All isolates causing alpha or beta hemolysis were not further evaluated. Similarly, further testing of any isolates whose colony morphology was consistent with that of the B. cereus group (B. cereus, B. mycoides, B. thurigensis, and B. anthrasis) were discontinued. Those isolates with the highest in vitro antimicrobial activity (anti-SE) were identified using the bioMerieux AP150 CHB test kit.
[034] Bacillus isolates identified using the above methods were screened for in vitro microbacterial inhibitory activity for Clostridium perfringens (CP) and Campylobacter jejuni. A similar coating method as described above was used, however the coatings were incubated anaerobically and NO was added to the coating medium.
[035] In an effort to cultivate high numbers of viable spores, a solid state fermentation medium was used. Only isolates which were able to grow and sporulate more than 1x101 spores per gram were selected for further evaluation. Three samples from each of the sporulated candidate cultures were diluted 1:9 in 0.9% sterile saline. Duplicate samples were subjected to room temperature for 30 minutes or 100°C for 10 minutes to assess the heat stability of candidate spores. Following heat treatments, spore solutions were diluted, seeded and incubated overnight at 37°C on TSA plates for colony formation unit determination. Only isolates whose spores lost less than 1 log1 unit after heat treatment were also evaluated.
[036] Isolates that underwent in vitro testing were evaluated using a series of in vivo tests illustrated in Figure 2. These isolates were selected for further analysis and in vivo experiments with turkeys and chicks due to their performance in in vitro tests. An antibiotic-free soy-corn starter diet for turkey, produced by the University of Arkansas Department of Poultry Sciences (Fayetteville, AR 72701) and formulated to meet or exceed the National Research Council requirements for critical nutrients in young turkeys and chicks was used as a basal diet for these experiments. Spores from candidate isolates were added to the basal diet at a concentration of approximately 10 ® cfu/gm feed and mixed with a rotary shaker for 15 minutes to distribute spores throughout the feed.
[037] Commercial fattening chickens/chicks and commercial turkeys were obtained at brooding day and orally fed by gavage with Salmonella typhimurium (ST) at a dose of approximately 105cfu/chick. They were then randomly assigned to groups: negative control (basal diet) or a group fed a basal diet containing spores from one or more candidate isolates (n=20/group). The turkeys and chicks were then marked, weighed, and placed in the closed pens appropriate for the treatment. Turkeys and chicks had freshly sliced pine as bedding material and had free access to food and water for the duration of the experiment. At the conclusion of the experiment, on or around day 10, the chicks and turkeys were weighed. The tonsils were aseptically removed and placed in Tetrathionate Broth. The caeca were homogenized and diluted 1:4 by weight with sterile saline. Total viable counts of ST were determined by plate dilutions on BGA plates with NO (25pg/mL) and nalidixic acid (NA; 20pg/mL) after 24h incubation at 37°C. The plates were examined for the presence of colonies typical of this strain of SP in BGA medium. Isolates which produce greater body weight gains than the control and lead to a recovery from ST-decrease were selected for another test, while unsuccessful isolates were discarded.
[038] Successful isolates from the above test were again incorporated into a poultry feed as described above. Spores from candidate isolates were added to the basal diet and mixed with a rotary shaker for 15 minutes to distribute spores throughout the feed. Commercial broiler chicks were obtained at brooding day and fed orally by gavage with Salmonella typhimurium (ST). They were then randomly assigned to groups: Negative control (basal diet) or a group fed a basal diet containing spores of one or more isolates. The chicks were then tagged, weighed, and placed in the closed pens appropriate for the treatment (n=20/group). Chicks had freshly sliced pine as bedding material and had free access to food and water for the duration of the experiment. At approximately 3 weeks of age all chicks were weighed then gavaged on Eimeria maxima (EM). On days 3-5 after EM challenge all chicks were challenged with Clostridium perfringens. At or near 4 weeks of age all chicks were weighed and the chick intestines were assigned a subjective labeling for necrotic enteritis lesions as described previously (Avian Diseases 51(4):834-839 (2007)). Isolates which significantly reduced (p<0.5) the severity of necrotic enteritis were kept for further evaluation.
[039] In a subsequent test, all successful isolates were evaluated for their ability to persist within the gastrointestinal tract of commercially farmed birds. Commercial broiler chicks were obtained on the day of brooding then separated into groups at random. These chicks were placed by group in isolating units. The chicks were fed a standard chicken feed which had been heat sterilized previously. On or around day 7, individual groups (n=20) of broiler chicks were orally gavaged with approximately 10° cfu of candidate isolates or sterile saline (as a negative control). The persistence of candidate isolates was assessed by enumerating individual bird intakes in most experiments. Many of the isolates tested dropped in numbers sharply such that through 72 hours after gavage, cfu with less than 1x103 cfu/Gm ingestion were enumerated, similarly declining for an expected intestinal passage time of approximately 46 hours, indicating that these isolates were not reproducing within the intestinal tract. However, some isolates were rediscovered at levels greater than 1x10' cfu/gm at 96 hours post-gavage. Such isolates were selected for further evaluation. Isolates which persisted longer than their expected half-life were selected for further evaluation.
[040] Using the selection processes a total of nine isolates were found to be potentially useful, alone or in combination with other isolates, as a probiotic or DFM for use in commercial poultry. These nine isolates include Bacillus subtilis strains AM0904 (NRRL Deposit Number B-50914), AM0911 (NRRL Deposit Number B-50915), NP122 (NRRL Deposit Number B-50910), and NP119B (NRRL Deposit Number B- 50909) and B. lichenlformis strains to include B1 (NRRL Deposit Number B-50907), B2 (NRRL Deposit Number B-50908), RW25 (NRRL Deposit Number B-50911), RW32 (NRRL Deposit Number B- 50912), and RW41 (NRRL Deposit Number B-50913).
[041] In a series of final tests, the isolates are retested not as individual isolates, but in a combination of 2 to 3 isolates. These combinations were subjected to the aforementioned in vivo tests and evaluated using the same parameters as above, as well as when comparing the performance of the individual isolates in these same tests. The best performing isolates from combinations of isolates were also used in field testing and were considered potential candidates for inclusion in a final product.
[042] Combinations of the isolates listed above may include, but are not limited to, the following: NP122, AM0904 and B2. This combination was shown to be effective when administered in a 5:5:1 ratio for NP122, B2 and AM0904 isolates respectively.
[043] When administered in the diet this combination was shown to be effective in producing a significant (p<0.05) reduction in Salmonella infection (50-90% decrease in recovery), mortality from necrotic enteritis and lesions (22% in controls to 0 % in treated), and improving body weight gain during periods of challenge by more than 50% when administered at a rate of 5x10°:5x106:1x106: spores per gram of ready-feed for isolates NP122, B2 and AM0904, respectively .
权利要求:
Claims (9)
[0001]
1. Probiotic formulation, characterized in that it comprises a bacterial isolate selected from the group Bacillus subtilis AM0904 (Deposit number NRRL B-50914), Bacillus subtilis AM0911 (Deposit number NRRL B-50915), Bacillus subtilis NP122 (Deposit number NRRL B -50910), Bacillus subtilis NP119B (Deposit number NRRL B-50909), B. licheniformis B1 (Deposit number NRRL B-50907), B. subtilis B2 (Deposit number B-50908), B. licheniformis RW25 (Deposit number B-50907 NRRL B-50911), B. licheniformis RW32 (Deposit number NRRL B-50912) and B. licheniformis RW41 (Deposit number NRRL B-50913), wherein the formulation comprises at least one Bacillus subtilis isolate and at least one at least one Bacillus licheniformis isolate, or at least two Bacillus subtilis isolates.
[0002]
2. Probiotic formulation, according to claim 1, characterized in that the bacterial isolate is capable of improving the health of the gastrointestinal tract in poultry.
[0003]
A probiotic formulation according to claim 2, characterized in that the improvement in the health of the gastrointestinal tract encompasses at least one of the potential reduction of bacterial pathogens of human food origin from the gastrointestinal tract of commercial poultry, the reduction of at least one of Salmonella, Campylobacter or Clostridium perfringens in the gastrointestinal tract of poultry, or an increase in daily weight gain of poultry.
[0004]
4. Probiotic formulation, according to claim 1, characterized in that a Bacillus subtilis isolate and a Bacillus licheniformis isolate, or two Bacillus subtilis isolates are between 0.5:1 and 3:1 colony forming units (CFU). ).
[0005]
A probiotic formulation according to claim 1, characterized in that Bacillus subtilis isolates comprise NP122, AM0904 or B2.
[0006]
6. Probiotic formulation, according to claim 5, characterized in that Bacillus subtilis NP122, B2 and AM0904 isolates are present in a ratio of 5:5:1 colony forming units (CFU).
[0007]
A probiotic formulation according to claim 1, characterized in that the formulation is configured to be administered through an agricultural animal feed substrate.
[0008]
8. Animal feed comprising the probiotic formulation of claim 1, characterized in that the feed comprises between 104 and 109 spores/gram of ready-to-eat feed.
[0009]
A probiotic formulation according to claim 1, characterized in that the bacterial isolate is capable of reducing the severity of necrotic enteritis in poultry and wherein the bacterial isolates are not capable of hemolysis.
类似技术:
公开号 | 公开日 | 专利标题
BR112013001107B1|2022-01-25|Methods and compositions including spore-forming bacteria for enhancing animal health
De Oliveira et al.2014|In ovo inoculation of chicken embryos with probiotic bacteria and its effect on posthatch Salmonella susceptibility
Forte et al.2016|Effects of two different probiotics on microflora, morphology, and morphometry of gut in organic laying hens
Molnár et al.2011|Effect of different concentrations of Bacillus subtilis on growth performance, carcase quality, gut microflora and immune response of broiler chickens
Stavric et al.2008|10 Microbial probiotics for pigs and poultry
Alkhalf et al.2010|Influence of probiotic supplementation on blood parameters and growth performance in broiler chickens
Fritts et al.2000|Bacillus subtilis C-3102 | improves live performance and microbiological status of broiler chickens
Kantas et al.2015|A feed additive containing Bacillus toyonensis | protects against enteric pathogens in postweaning piglets
Impey et al.1982|Competitive exclusion of salmonellas from the chick caecum using a defined mixture of bacterial isolates from the caecal microflora of an adult bird
Latorre et al.2014|Evaluation of germination, distribution, and persistence of Bacillus subtilis spores through the gastrointestinal tract of chickens
Ripamonti et al.2009|Administration of Bacillus coagulans in calves: recovery from faecal samples and evaluation of functional aspects of spores
Soerjadi et al.1981|The influence of lactobacilli on the competitive exclusion of paratyphoid salmonellae in chickens
Zhang et al.2016|Effect of a potential probiotics Lactococcus garvieae B301 on the growth performance, immune parameters and caecum microflora of broiler chickens
Wolfenden et al.2010|Evaluation of a screening and selection method for Bacillus isolates for use as effective direct-fed microbials in commercial poultry
Amer et al.2012|A comparison between the effects of a probiotic and an antibiotic on the performance of Desi chickens
Strompfova et al.2005|New probiotic strain Lactobacillus fermentum AD1 and its effect in Japanese quail
Al‐Tarazi et al.2003|Effect of dietary formic and propionic acids on Salmonella pullorum shedding and mortality in layer chicks after experimental infection
US7744868B2|2010-06-29|Composition and method for inhibiting Salmonella and Campylobacter colonization in poultry
Dunlop et al.1998|Prevalences of resistance to seven antimicrobials among fecal Escherichia coli of swine on thirty-four farrow-to-finish farms in Ontario, Canada
Thongsong et al.2008|Effects of the addition of probiotic containing both bacteria and yeast or an antibiotic on performance parameters, mortality rate and antibiotic residue in broilers
Castañeda et al.2021|In ovo administration of Bacillus subtilis serotypes effect hatchability, 21-day performance, and intestinal microflora
Ghosh et al.2015|Antibiotic resistance in Enterococci: A food safety perspective
Pospíšková et al.2013|Effect of probiotics in the pig nutrition on the pathogenic bacteria counts in the gut
Telg et al.2009|Efficacy testing of a defined competitive exclusion product in combination with fructooligosaccharide for protection against Salmonella Typhimurium challenge in broiler chicks
KR20140005004A|2014-01-14|A feed composition for poultry
同族专利:
公开号 | 公开日
WO2012009712A3|2012-05-10|
BR112013001107A2|2020-08-04|
EP2593187A2|2013-05-22|
US20130136695A1|2013-05-30|
US9005601B2|2015-04-14|
EP2593187A4|2014-04-09|
WO2012009712A2|2012-01-19|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US4335107A|1978-06-05|1982-06-15|Snoeyenbos Glenn H|Mixture to protect poultry from salmonella|
FI59925C|1980-01-11|1981-11-10|Esko Viljo Nurmi|FOERFARANDE FOER FRAMSTAELLNING AV ETT BAKTERIEPREPARAT ANVAENDBART FOER FOERHINDRANDE AV SALMONELLAINFEKTION HOS FJAEDERFAE|
FI840816A0|1984-03-01|1984-03-01|Farmos Oy|BAKTERIEPREPARAT|
DE3790919T1|1987-02-24|1989-03-23|Inst Mikrobiologii Virusologii|MEDICINAL PRODUCTS FOR PROPHYLAXIS AND TREATMENT OF GASTROINFINAL DISEASES OF AGRICULTURAL LIVESTOCK|
US4910024A|1988-07-05|1990-03-20|Micro Chemical, Inc.|Method and apparatus for administering live bacteria as feed additives to livestock and poultry|
DE69422501T2|1993-03-16|2000-06-15|Us Agriculture|COMPETITIVELY DISPLACING MUCALINE FLORA|
GB9416841D0|1994-08-19|1994-10-12|Finnfeeds Int Ltd|An enzyme feed additive and animal feed including it|
US6506389B2|1995-10-20|2003-01-14|Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek |Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors|
US5807546A|1996-10-11|1998-09-15|The United States Of America As Represented By The Secretary Of Agriculture|Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria|
US6017525A|1997-04-02|2000-01-25|Logan; Walter T.|Poultry house litter treatment|
US6461607B1|1998-08-24|2002-10-08|Ganeden Biotech, Inc.|Probiotic, lactic acid-producing bacteria and uses thereof|
US6110455A|1999-01-20|2000-08-29|Ms Bioscience|Method for encouraging poultry to distribute and ingest competitive exclusion products|
DE10105347A1|2001-02-05|2002-08-22|Nutrinova Gmbh|Sorbic acid preparation containing probiotics as a feed additive in livestock rearing|
RU2203947C1|2001-09-26|2003-05-10|Закрытое акционерное общество "КУЛ"|Strain of bacterium bacillus licheniformis used for preparing probiotic preparation designated for prophylaxis and treatment of gastroenteric diseases in animals, poultry and fishes|
EP1314359A1|2001-11-21|2003-05-28|N.V. Seghers Nutrition Sciences|Growth promoter composition for animals|
US20040241150A1|2002-12-19|2004-12-02|Hargis Billy M.|Defined competitive exclusion cultures for food borne pathogens|
US7354757B2|2002-07-22|2008-04-08|Agtech Products, Inc.|Lactobacillus brevis strain|
RU2252956C2|2002-11-11|2005-05-27|Закрытое акционерное общество "КУЛ"|Probiotic additive and method for production thereof|
US7247299B2|2002-11-27|2007-07-24|Kemin Industries, Inc.|Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens|
WO2004080200A1|2003-03-11|2004-09-23|Inatech International Inc.|Probiotic micro-organisms and uses thereof|
RU2006107931A|2003-08-14|2006-07-27|Дзе Байо Бэлэнс Корпорейшн |BACTERIAL STRAINS INCLUDING THEIR COMPOSITIONS AND THEIR PROBIOTIC USE|
US7718415B1|2003-09-23|2010-05-18|Pioneer Hi-Bred International, Inc.|Acetyl esterase producing strains and methods of using same|
US20100074873A1|2004-05-25|2010-03-25|Watson James B|Live bacteria product|
EP1967196A4|2005-11-18|2009-10-14|Idemitsu Kosan Co|Harmful bacterium control agent containing bacillus thuringiensis|
US20080057047A1|2005-11-29|2008-03-06|Benedikt Sas|Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases|
US7754469B2|2005-11-30|2010-07-13|Agtech Products, Inc|Microorganisms and methods for treating poultry|
US20080044501A1|2006-08-16|2008-02-21|Genebiotech Co. Ltd.|Fermented soybean products and methods of producing them|
EP2117354B1|2006-12-18|2018-08-08|Advanced BioNutrition Corp.|A dry food product containing live probiotic|
EP2011858B1|2007-07-06|2012-05-30|Chr. Hansen A/S|A bile resistant bacillus composition secreting high levels of phytase|
CN101580799B|2008-05-14|2011-01-12|北京大北农科技集团股份有限公司|Micro-ecological preparation and application thereof|
JP6084771B2|2008-09-17|2017-02-22|バイエル クロップサイエンス エルピーBayer Cropscience Lp|How to use Bacillus subtilis strains to improve animal health|
US8227235B2|2008-12-10|2012-07-24|Alpharma, Llc|Compositions and methods for controlling diseases in animals|
CN101569375A|2009-06-05|2009-11-04|李守凡|Novel biological feed for cattle|
WO2012009712A2|2010-07-16|2012-01-19|The Board Of Trustees Of The University Of Arkansas|Methods and compositions including spore-forming bacteria for increasing the health of animals|
WO2012044984A1|2010-09-30|2012-04-05|The Board Of Trustees Of The University Of Arkansas|Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads|
US9023345B2|2011-03-01|2015-05-05|Novus International, Inc.|Methods for improving gut health|
WO2014022572A1|2012-08-01|2014-02-06|Pacific Vet Group-Usa, Inc.|Probiotic for amelioration of coccidiosis vaccine reaction|WO2012009712A2|2010-07-16|2012-01-19|The Board Of Trustees Of The University Of Arkansas|Methods and compositions including spore-forming bacteria for increasing the health of animals|
WO2012044984A1|2010-09-30|2012-04-05|The Board Of Trustees Of The University Of Arkansas|Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads|
WO2014022572A1|2012-08-01|2014-02-06|Pacific Vet Group-Usa, Inc.|Probiotic for amelioration of coccidiosis vaccine reaction|
US8906668B2|2012-11-23|2014-12-09|Seres Health, Inc.|Synergistic bacterial compositions and methods of production and use thereof|
CN110917220A|2013-02-04|2020-03-27|赛里斯治疗公司|Therapeutic compositions and methods of use thereof|
US10973861B2|2013-02-04|2021-04-13|Seres Therapeutics, Inc.|Compositions and methods|
JP2016519664A|2013-03-15|2016-07-07|セレス セラピューティクス インコーポレイテッド|Microbial composition and method based on network|
WO2015077794A1|2013-11-25|2015-05-28|Seres Health, Inc.|Synergistic bacterial compositions and methods of production and use thereof|
US9956282B2|2013-12-16|2018-05-01|Seres Therapeutics, Inc.|Bacterial compositions and methods of use thereof for treatment of immune system disorders|
US10716310B2|2014-03-13|2020-07-21|Phibro Animal Health Corporation|Strains of bacillus for inhibiting foodborne pathogens|
WO2015175667A1|2014-05-13|2015-11-19|Microbial Discovery Group, Llc|Direct-fed microbials and methods of their use|
US20170246222A1|2014-10-08|2017-08-31|Novozymes A/S|Bacillus Strains with Fast Germination and Antimicrobial Activity against Clostridium|
US20180264052A1|2015-01-23|2018-09-20|Novozymes A/S|Bacillus Strains Improving Health and Performance of Production Animals|
EP3247788A1|2015-01-23|2017-11-29|Novozymes A/S|Bacillus strains improving health and performance of production animals|
AU2016291641B2|2015-07-14|2021-02-25|Board of Trustees of The University of Arkansas acting for and on behalf of The University of Arkansas System, Division of Agriculture, University of Arkansas|Compositions, probiotic formulations and methods to promote digestion and improve nutrition in poultry|
US20180235191A1|2015-08-20|2018-08-23|Api Holdings, Llc|Formulations and methods for promoting honeybee health|
US10201574B1|2015-09-16|2019-02-12|Church & Dwight Co., Inc.|Methods of microbial treatment of poultry|
AU2015411375B2|2015-10-09|2019-10-24|Axichem Ab|Bird feed and in particular poultry feed, comprising synthetic capsaicinoid derivatives and such feed for prohylactic use or treatment of salmonella infection|
ES2883164T3|2016-01-25|2021-12-07|Novozymes As|Method to reduce microbial bloom in poultry crops|
US10335440B2|2016-02-29|2019-07-02|Microbial Discovery Group, Llc|Direct-fed microbials|
RU2018144879A3|2016-05-25|2020-10-02|
KR20190128200A|2017-03-14|2019-11-15|시에이치알. 한센 에이/에스|Bacillus subtilis strains improve animal function parameters|
WO2021146582A1|2020-01-17|2021-07-22|AgBiome, Inc.|Compositions and methods for controlling undesirable microbes and improving animal health|
法律状态:
2020-08-18| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
2020-09-01| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
2021-04-13| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|
2021-10-13| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|
2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|
2021-11-30| B15K| Others concerning applications: alteration of classification|Free format text: A CLASSIFICACAO ANTERIOR ERA: A61P 31/04 Ipc: A61K 35/742 (2015.01), C12N 1/20 (2006.01), A23K 1 |
2021-12-14| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
2022-01-25| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
优先权:
申请号 | 申请日 | 专利标题
US36518810P| true| 2010-07-16|2010-07-16|
US61/365,188|2010-07-16|
PCT/US2011/044326|WO2012009712A2|2010-07-16|2011-07-18|Methods and compositions including spore-forming bacteria for increasing the health of animals|
[返回顶部]